viewAcasti Pharma Inc

Acasti Pharma looking forward to the unblinding of its TRILOGY 2 trial data around end of this month

The group submitted its Statistical Analysis Plan (SAP) for the TRILOGY 2 Phase 3 trial to the FDA on July 31

Acasti Pharma Inc -
Topline results from the first study, TRILOGY 1, did not reach statistical significance due to an unusually large placebo effect

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has provided an update on its progress towards a possible new drug application (NDA) for its flagship drug CaPre aimed at treating hypertriglyceridemia and said it expects topline results from its second Phase 3 trial around the end of this month, and posted its first-quarter results.

The group already revealed on July 31 that it submitted its Statistical Analysis Plan (SAP) for the TRILOGY 2 Phase 3 trial to the US Food & Drug Administration (FDA), the data of which it remains blinded to.

READ: Acasti Pharma submits Statistical Analysis Plan to FDA for TRILOGY 2 Phase 3 trial of flagship drug CaPre

"With the TRILOGY 2 SAP finalized and now submitted to the FDA, we continue to advance the process towards unblinding of our TRILOGY 2 clinical data," said Jan D’Alvise, CEO of Acasti in a statement on Thursday.

"We believe if TRILOGY 2 can achieve statistical significance, and if the pooled efficacy results with TRILOGY 1 using the Intent to Treat population also reaches significance, we can proceed with our Pre-NDA meeting where we intend to discuss with the FDA the use of this data to support an NDA filing.

"We look forward to the unblinding of TRILOGY 2 data and reporting our findings, concurrent with a conference call update on or about August 31, 2020," he added.

The process is all a result of the fact that topline results from the first study - TRILOGY 1- of Capre did not reach statistical significance due to an unusually large placebo effect, which prompted a 'rigorous' review of data from that trial.

That review revealed a rapid, significant and sustained reduction in TG levels between screening (during qualification) and the time of patient randomization (prior to patients starting on either drug or placebo), which Acasti has called a "Pre-randomization Triglyceride (TG) Normalization".

Acasti provided all of the TRILOGY 1 background information and accompanying data to the US Food and Drug Administration (FDA) in a Type C briefing package, which was filed on April 29, 2020.

The FDA then confirmed that pivotal efficacy analyses for TRILOGY 2 will be performed on the full Intent to Treat (ITT) population, as contemplated in the original Statistical Analysis Plan (SAP).

On Thursday, Acasti also reported its first-quarter results to end June, which showed a loss from operations of C$4.1 million, down from a loss of C$8 million for the same period last year. The decrease was due mainly to a reduction in research contract expenses, it said.

Cash and cash equivalents at period end came in at C$12.1 million, compared to C$16.0 million at June 30, 2019.

Acasti said it believes that its current cash will fully fund operations through the first calendar quarter of 2021.

Contact the author at [email protected]

Quick facts: Acasti Pharma Inc

Price: 0.77 CAD

Market: TSX-V
Market Cap: $74.61 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...


Full interview: Acasti has 'put its finger on something very interesting' in...

Acasti Pharma Inc (NASDAQ:ACST)(CVE:ACST) COO Pierre Lemieux tells Proactive the last patient completed their final visit in its TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia. Lemieux says the Quebec-based company is on its way to reporting results by the end of...

on 11/26/2019

3 min read